Warning letter
Pride and Power, Inc.: warning letter of Mar 3, 2003
FDA warning letter UCM147340 · Dallas District Office
Key facts
| Reference number | UCM147340 |
|---|---|
| Company | Pride and Power, Inc. |
| Subject | CGMP in Manufacturing, Processing, Packing or Holding/CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | Mar 3, 2003 |
| Posted date | Mar 3, 2003 |
| Issuing office | Dallas District Office |
| Product type | Drugs |
| CFR sections cited | 211.67(b), 211.84(d)(2), 211.110(a), 211.122(a), 211.186(b)(9), 211.165(a), 211.198(a), 211.188, 310.527, 330.1, 358.701, 358.710 and 4 more |
| Country | 3 |
| Inspection city | Houston |
| Inspection ZIP | 77021-1424 |
| Inspection start date | Jan 22, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: